// App-Quantinova.ai

1917 : Gastrointestinal Events and Management Strategies for Patients with Acute Myeloid Leukemia (AML) in First Remission Receiving CC-486 in the Randomized, Placebo-Controlled, Phase III QUAZAR AML-001 Maintenance Trial

Researchers

Presenter

  • Farhad Ravandi

Principal Investigators

  • Dominik Selleslag

  • Pau Montesinos

  • Hamid Sayar

  • Maurizio Musso

  • Angela Figuera Alvarez

  • Hana Safah

  • William Tse

  • Sang Kyun Sohn

  • Devendra Hiwase

  • Timothy Chevassut

  • Francesca Pierdomenico

  • Ignazia La Torre

  • Barry Skikne

  • Keshava Kumar

  • Qian Dong

  • C.L. Beach

  • Herv Dombret

Medical Centers

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Kent & Canterbury Hospital, Kent, United Kingdom

  • AZ Sint-Jan Brugge-Oostende, Brugge, Belgium

  • Hospital Universitari i Politecnic La Fe, Valencia & CIBERONC, Instituto Carlos III, Madrid, Spain

  • Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN

  • La Maddalena - Casa di Cura, Palermo, Italy

  • Hospital Universitario La Paz, Madrid, Spain

  • Section of Hematology and Medical Oncology, Department of Medicine, Tulane University, New Orleans, LA

  • University of Louisville, School of Medicine, Louisville, KY

  • Kyungpook National University Chilgok Hospital, Deqgu, Korea, Republic of

  • Royal Adelaide Hospital, Adelaide, Australia

  • Haematology Department, Brighton & Sussex University Hospitals NHS Trust, Brighton, United Kingdom

  • Portuguese Institute of Oncology, Lisbon, Portugal

  • Celgene International Sàrl, a Bristol Myers Squibb Company, Boudry, Switzerland

  • Kansas University Medical Center, Kansas City, KS

  • Bristol-Myers Sqiubb, Princeton, NJ

  • Hopital Saint-Louis, Assistance Publique - Hopitaux De Paris (AP-HP), Paris, FRA

  • Institut de Recherche Saint-Louis, Université de Paris,Paris,France

Locations

  • United States

  • United Kingdom

  • Belgium

  • Spain

  • Italy

  • Republic of South Korea

  • Australia

  • Portugal

  • Switzerland

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute myelocytic leukemia

Biomarkers

  • N/A

Drug/Treatment

  • CC-486

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Controlled

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved